Arthur Levin, PhDExecutive Vice President, R&D at Avidity Biosciences LLC
Artificial Intelligence (AI) can drive cars, beat humans at their own games and transcribe speech. Biology and medicine present much greater challenges, but the recent exponential growth in biomedical data has made AI assisted drug development a reality. Brendan Frey, a pioneer in this field, will discuss how Deep Genomics is using AI for target discovery and drug development, and give his perspective on the opportunities and challenges that lie ahead,
such as guaranteeing prediction accuracy and establishing trust with clinicians and regulators.